Compositions and methods to inhibit kidney stone growth

Abstract

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

1 . An oral dosage form or a plurality of dosage forms comprising at least three ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa. 
     
     
         2 . The oral dosage form or plurality of dosage forms according to  claim 1  comprising three active ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa. 
     
     
         3 . The oral dosage form or plurality of dosage forms according to  claim 2  selected from:
 a) an oral dosage form or plurality of dosage forms comprising citric acid, magnesium citrate, and phytin; 
 b) an oral dosage form or plurality of dosage forms comprising citric acid, phytin, and pyridoxine; 
 c) an oral dosage form or plurality of dosage forms comprising citric acid, pyridoxine, and musa; 
 d) an oral dosage form or plurality of dosage forms comprising citric acid, phytin, and musa; 
 e) an oral dosage form or plurality of dosage forms comprising citric acid, magnesium citrate, and pyridoxine; 
 f) an oral dosage form or plurality of dosage forms comprising citric acid, magnesium citrate, and musa; 
 g) an oral dosage form or plurality of dosage forms comprising magnesium citrate, phytin, and pyridoxine; 
 h) an oral dosage form or plurality of dosage forms comprising magnesium citrate, pyridoxine, and musa; 
 i) an oral dosage form or plurality of dosage forms comprising magnesium citrate, phytin, and musa; and 
 j) an oral dosage form or plurality of dosage forms comprising phytin, pyridoxine, and musa. 
 
     
     
         4 . The oral dosage form or plurality of dosage forms according to  claim 1  comprising four active ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa. 
     
     
         5 . The oral dosage form or plurality of dosage forms according to  claim 1  comprising citric acid, magnesium citrate, phytin, pyridoxine, and musa. 
     
     
         6 . A method of treating or inhibiting formation of kidney stones comprising administering to a patient in need thereof the oral dosage form or the plurality of dosage forms of  claim 1 . 
     
     
         7 . A method of inhibiting growth of calcium oxalate crystals comprising contacting an aqueous solution comprising calcium oxalate with the oral dosage form or the plurality of dosage forms of  claim 1 .